Artificial intelligence in cardiovascular medicine: systematic review of randomized controlled trials
European Heart Journal - Digital Health

Abstract
Artificial intelligence (AI) holds considerable promise for improving cardiovascular care, but prior to widespread adoption, AI-powered tools require evaluation in randomized trials. We systematically reviewed the current evidence from randomized trials of AI tools in cardiovascular medicine.
We conducted a systematic review of randomized trials comparing AI tools vs. standard care in cardiovascular medicine. PubMed, the Cochrane Central Register of Controlled Trials, Scopus, and the International Clinical Trials Registry Platform were searched from 1 January 2018, to 10 April 2026. Screening and full-text review were performed by three independent reviewers and risk of bias was assessed using the RoB 2 criteria. Of 11 151 identified records, 8599 remained after removal of duplicates. Following screening and full-text review, 25 trials met the eligibility criteria. These trials evaluated AI tools in acute cardiovascular care (
Evidence from randomized trials evaluating AI tools in cardiovascular medicine is limited, and most trials have a high risk of bias. Wider implementation of AI tools into practice requires robust, international, multi-centre randomized trials that evaluate patient-relevant outcomes, ensure external validity, and adhere to reporting guidelines.
PROSPERO CRD420251019264
Contributors

Tiffany Péquignot
Author

Ivo Strebel
Author

Wayne Zeng
Author

Sven Knecht
Author

Julia Freiermuth
Author

Arnaud Tanguy Champetier
Author

Dimitrios Doudesis
Author

Kuan Ken Lee
Author

Andrew R Chapman
Author

Gregor Leibundgut
Author

Felix Mahfoud
Author

Gary S Collins
Author

Richard D Riley
Author

Nicholas L Mills
Author

Christian Mueller
Author
You may be interested in









